All In Biotech

Free tool

FAERS Monitor: Stimate

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020355 or its brand name (Stimate, Desmopressin Acetate). Reports on generic versions are filed under their own applications.

Reports

2,425

Serious

1,645

68% of reports

Hospitalization

890

Death reported

150

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hyponatraemia237
  • headache177
  • drug ineffective176
  • nausea125
  • fatigue102
  • off label use94
  • vomiting94
  • dizziness79
  • flushing67
  • pain66
  • diarrhoea61
  • epistaxis61
  • condition aggravated59
  • recalled product administered57
  • malaise56

Reports by year received

View as table
YearReports
200420
200521
200634
200734
2008113
200996
201095
201190
2012103
201342
201484
2015104
2016190
2017164
2018141
2019131
2020144
2021140
2022127
2023128
2024173
2025154
202697

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,734 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
recalled product administeredSignal5752.140.32,793
hyponatraemiaSignal23736.732.58,170
epistaxisSignal617.15.5313
flushingSignal675.74.5257
headacheSignal1772.42.1155
vomiting941.71.429
condition aggravated591.71.316
dizziness791.41.18
nausea1251.41.213
drug ineffective1761.21.04
fatigue1021.10.92
malaise561.10.90
pain660.90.70
off label use940.90.80
diarrhoea610.80.62

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.